Interview with André Choulika, President, France Biotech
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
Address: 420 Rue d’Estienne D’orves 92700 Colombes,France
Tel: +33 1 47 29 44 35
Web: http://www.ucb.com/worldwide/
With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in two therapeutic areas – CNS and Immunology. Worldwide, UCB has annual turnover of €3.6 billion, over 20% of which is reinvested into R&D with the aims of being a next generation biopharma leader.
In France, the laboratory has over 150 research partnerships and does over €190 million in business through while employing 140 people.
Central Nervous System
Immunology
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
